CN1342491A - Medicine 'Suyusan' for treating intractable ulcer - Google Patents
Medicine 'Suyusan' for treating intractable ulcer Download PDFInfo
- Publication number
- CN1342491A CN1342491A CN01140510A CN01140510A CN1342491A CN 1342491 A CN1342491 A CN 1342491A CN 01140510 A CN01140510 A CN 01140510A CN 01140510 A CN01140510 A CN 01140510A CN 1342491 A CN1342491 A CN 1342491A
- Authority
- CN
- China
- Prior art keywords
- powder
- powdery
- medicine
- suyusan
- syngnathus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 18
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title description 3
- 239000000843 powder Substances 0.000 claims abstract description 62
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- 229960002790 phenytoin sodium Drugs 0.000 claims abstract description 13
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 13
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 13
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 13
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims abstract description 13
- 229910021538 borax Inorganic materials 0.000 claims abstract description 12
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 12
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 235000014443 Pyrus communis Nutrition 0.000 claims description 17
- 241000646357 Monopterus cuchia Species 0.000 claims description 15
- 241001478428 Syngnathus Species 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 11
- 241000180649 Panax notoginseng Species 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 4
- 244000293323 Cosmos caudatus Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 230000035876 healing Effects 0.000 abstract description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 10
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A medicine "Suyusan" for treating intractable ulcer is prepared from phenytoin sodium, sodium benzoate, VC and 5 Chinese medicinal materials including pearl layer powder, borax, borneol, etc. through uniformly mixing according to defined quantity. Its advantages include speeding up healing, no any toxic by-effect, high cure rate up to 98.7%, and no recurrence.
Description
Technical field
The present invention relates to a kind of surgical medicine product, particularly medicine ' Suyusan ' for treating intractable ulcer.It is suitable for mucocutaneous intractable, chronic ulcerative treatment of diseases medicine, belongs to topical drug.
Background technology
Mucocutaneous intractable, chronic ulcer be clinical in common frequently-occurring disease.At present, often adopt antibiotic to infuse or oral to the treatment of this kind disease, in addition the Chang Gui therapy of changing dressings, promptly to the wound circumference skin degerming, normal saline cleans a wound, then with flap coverages such as vaseline oil sliver or gentamycin sliver, enclosing cover dressing, wrapping.Adopt the conventional therapy of changing dressings to play and protect wound as far as possible; avoid infecting again; the patient only relies on self-ability that wound is healed gradually; like this; owing to lack the essential condition of local nutritional labeling of wound and removing the necrotic tissue and promoting granulation; so wound healing is slower, causes the wound protracted course of disease sometimes, reaches several months, several years even decades.And adopt the antibiotic medicine treatment easily to cause drug resistance and anaphylaxis etc.
Summary of the invention
The object of the present invention is to provide a kind of medicine ' Suyusan ' for treating intractable ulcer, it can overcome the deficiency of prior art, and collection nutrition, sterilization, antibacterial, convergence, improve little multiple effect such as follow, help wound matrigel fibril and proteinic synthetic, the speed of accelerating wound healing can be impelled wound healing effectively.
The present invention measures pear powder layer, syngnathus and mud eel powder and process pulverizing, porphyrize, the Borax that sieves, Borneolum Syntheticum, Radix Notoginseng powder, sodium benzoate, phenytoin Sodium, vitamin C in accordance with regulations uniform mixing and forms. and its prescription is by mass percentage following:
Pear powder layer 18-50%; Syngnathus and mud eel powder 10-40%; Borax 2-15%; Borneolum Syntheticum 1-5%; Radix Notoginseng powder 1.3-9%; Sodium benzoate 0.02-0.3%; Phenytoin Sodium 5-30%; Vitamin C 0.5-5%.
Described pear powder layer is formed by southern pearl powder and Margarita layer powder uniform mixing, and they the two composition by weight ratio is 1: 4.
Described syngnathus and mud eel powder is formed by Endoconcha Sepiae, Os Draconis and Monopteri albi dry powder uniform mixing, and their threes' composition by weight ratio is 1: 1: 1. wherein, Monopteri albi dry powder is from powder process, it by bright Monopteri albi through dry, porphyrize, sieving gets final product.All the other are all on sale on market.
Pear powder layer in this prescription is a composite powder, wherein contains 20 kinds of natural amino acids, natural activity calcium and ferrum, zinc, manganese, germanium, selenium and other trace elements, and utilization very easily is absorbed by the body.Antioxidant in its energy human activin, as superoxide dismutase, glutathion peroxidase etc., thus can stop the damage of radical pair cell membrane, and the various enzymatic activitys of energy human activin.Pear powder layer is nutrition, active substance, and it helps activating the metabolic activity of mucocutaneous cell and tissue, promotes tissue repairing ability, improves blood circulation, quickens collagen fiber and proteinic synthetic.Promote the healing time of granulation new life, shortening intractable ulcer.And syngnathus and mud eel powder also is a composite powder, and it has removing dampness, absorbing toxin and the effect of granulation promoting removing the necrotic tissue, can help the granulation growth, quickens granulation promoting and holds back mouth.Borneolum Syntheticum has that ulcer is rancid, the hot and suffocating fire-toxin that looses, sterilization, antipruritic pain, effect that dirt eliminating is smelly.Sodium benzoate has antibacterial, anti-corrosion function.Aminoacid in phenytoin Sodium and the pear powder layer is collaborative, and it is synthetic to promote fibrocyte to finish collagen fiber.Vitamin C has sterilization, bacteriostasis.
In a word, above-mentioned all components matching have the comprehensive effect of heat-clearing and toxic substances removing, removing the necrotic tissue and promoting granulation, dispersing swelling and dissipating binds, sterilization, antibacterial, absorbing toxin, the growth of promotion granulation and wound healing.
The present invention mainly is that compositions such as utilization natural amino acid and various trace elements are made, multiple effects such as its collection nutrition, sterilization, antibacterial, convergence, microcirculation improvement, and helping wound matrigel fibril synthesizes with proteinic, the speed of accelerating wound healing.So its good effect can make healing speed accelerate, and is without any side effects, can avoid wound face to infect effectively again, and, the generation of drug resistance and allergic phenomena can not caused.Average cure rate to mucocutaneous intractable, chronic ulcer reaches 98.7%.Simultaneously, it also has workable, is convenient to the characteristics of applying in medical institutions at different levels.
The specific embodiment
Describe the specific embodiment of the present invention in detail below in conjunction with embodiment.
Embodiment 1:
The present invention forms by following prescription uniform mixing.
Pear powder layer 18%; Syngnathus and mud eel powder 38%; Powdery Borax 2%; Powdery Borneolum Syntheticum 2.35%; Radix Notoginseng powder 9.0%; Powdery phenytoin Sodium 30%; Powdery sodium benzoate 0.15%; Powdery vitamin C 0.5%.
Described pear powder layer is formed by southern pearl powder 1 part (parts by weight) and 4 parts of (parts by weight) uniform mixing of Margarita layer powder, and southern pearl powder and Margarita layer powder are all on sale on market, easily purchase.Described syngnathus and mud eel powder is by 1 part of Endoconcha Sepiae (parts by weight), and Os Draconis 1 part (parts by weight) and 1 part of (parts by weight) uniform mixing of Monopteri albi dry powder form.Except that Monopteri albi dry powder is from powder process, all the other two kinds all on sale on market, easily purchases.
Embodiment 2:
The present invention forms by following prescription uniform mixing.
Pear powder layer 32%; Syngnathus and mud eel powder 40%, powdery Borax 10%; Powdery Borneolum Syntheticum 2.0%; Radix Notoginseng powder 1.3%; Powdery phenytoin Sodium 10.68%; Powdery sodium benzoate 0.02%; Powdery Catergen .0%.Other are with embodiment 1.
Embodiment 3:
The present invention forms by following prescription uniform mixing.
Pear powder layer 36%; Syngnathus and mud eel powder 30%; Powdery Borax 10%; Powdery Borneolum Syntheticum 1.5%; Radix Notoginseng powder 3.3%; Powdery phenytoin Sodium 14%; Powdery sodium benzoate 0.2%; Powdery vitamin C 5%.Other are with embodiment 1.
Embodiment 4:
The present invention forms by following prescription uniform mixing.
Pear powder layer 50%; Syngnathus and mud eel powder 10%; Powdery Borax 8%; Powdery Borneolum Syntheticum 3.0%; Radix Notoginseng powder 6.7%; Powdery phenytoin Sodium 21%; Powdery sodium benzoate 0.3%; Powdery vitamin C 1.0%.Other are with embodiment 1.
Embodiment 5:
The present invention forms by following prescription uniform mixing.
Pear powder layer 45%; Syngnathus and mud eel powder 31%; Powdery Borax 9.5%; Powdery Borneolum Syntheticum 3.0%; Radix Notoginseng powder 2.3%; Powdery phenytoin Sodium 6.0%; Powdery sodium benzoate 0.2%; Powdery vitamin C 3.0%.Other are with embodiment 1.
Embodiment 6:
The present invention forms by following prescription uniform mixing.
Pear powder layer 39%; Syngnathus and mud eel powder 33%; Powdery Borax 9.0%; Powdery Borneolum Syntheticum 2.0%; Radix Notoginseng powder 4.3%; Powdery phenytoin Sodium 8.5%; Powdery sodium benzoate 0.2%; Powdery vitamin C 4.0%.Other are with embodiment 1.
Embodiment 7:
Pear powder layer 40%; Syngnathus and mud eel powder 20%; Powdery Borax 15%; Powdery Borneolum Syntheticum 1.0%; Radix Notoginseng powder 3.75%; Powdery phenytoin Sodium 17%; Powdery sodium benzoate 0.25%; Powdery vitamin C 3.0%.Other are with embodiment 1.
The test example:
1, clinical observation on the therapeutic effect
Adopt the present invention to carry out observation of curative effect case 618 examples in clinical practice, these cases all are after treating with conventional antibiotic and the routine method of changing dressings, the long-term disunion person of wound.In the long-term efficacy of these cases is observed, remove for some reason as reasons termination therapist 22 exceptions such as death, financial difficulties actual observation case 596 examples.Wherein, chronic traumatic ulcer 414 examples are all cured; Tissue necrosis 2 examples of festering after the chemotherapeutics extravasation are all cured; Decubital ulcer 59 examples are not cured 2 examples, and cure rate is 96.61%; Eczema 48 examples are all cured; Diabetic foot 20 examples are not cured 1 example, and cure rate is 95%; Blood stasis postoperative infection 30 examples are all cured; Furuncle and phyma diabrosis 9 examples are all cured; Cancer postoperative wound disunion 14 examples are all cured.Average cure rate reaches 98.7%.In the case of these observations, the shortest person of the course of disease 13 days, elder reaches 32 years.And in treatment clinical course, the course of treatment, the shortest person such as eczematosis patient can cure in 2 days, and other sick kinds 7 days the shortest courses of treatment of patient reach 46 days most.
2, model case for example
(1) patient, man, 58 years old, case number: 001.This patient in July, 92 is because of suffering from postoperative rectal cancer, intravenous drip chemotherapeutics vincristine, be seeped into outward and scratch side 9 * 4cm ulcer surface on the left wrist, the wound stench, secretions is many, tendon exposed, purple is to pink darkly outside to inside certainly for edge of wound, and thumb swells and ache, limitation of activity, conventional therapy did not have improvement in 8 months, adopted powder treatment of the present invention 46 days, wound healing, thumb is swollen to disappear, and movable function recovers.
(2), the patient, man, 65 years old, case number: 106, residual about 4 * 2cm chronic ulcer after the left leg wound does not heal through 3 years wound surface of conventional dressing change, adopt the present invention to treat 4 times, the next day once, wound surface is significantly dry, granulation is fresh, the surrounding skin pinkiness, show blood for good, skin begins to the centre growth, and 5 (next day once) healings fully continue to change dressings.
(3), the patient, man, 85 years old, case number: 392, because of the back long-term bed of fracturing, left heel rear portion decubital ulcer, fail to heal through 10 months conventional therapies, go to a doctor wound 4 * 3cm on October 20th, 2000, reach 1.5cm deeply, local skin is canescence, sclerosis, periphery is blue, the wound exudate moderate adopts the present invention to treat 38 days, fully healing.
(4), the patient, the man, 66 years old, case number: 046, because of carbon monoxide poisoning is plant man's shape several months, because large and small fecal incontinence forms perineal position eczema, companion's edema of scrotum adopts the present invention's treatment, change dressings 2 times, once-a-day, i.e. recovery from illness.
(5), the patient, man, 40 years old, case number: 405.Right side cheek furuncle and phyma squeeze broken after, fester and connect with the oral cavity.Successively treated 13 days with conventional method at hospital surgery and private clinic, nothing alleviates, and goes to a doctor, and checks: top, cheek corners of the mouth place, right side lump 4 * 4 * 3cm, and the right side facial swelling, there are 3 place's ulceration wounds the lump center, is perforation with the oral cavity, difficulty in opening mouth.Adopt drainage treatment of the present invention 9 times, the next day once, wound surface heals fully.
Claims (3)
1, a kind of medicine ' Suyusan ' for treating intractable ulcer contains pear powder layer, syngnathus and mud eel powder, Borax, Borneolum Syntheticum, Radix Notoginseng powder, sodium benzoate, phenytoin Sodium and vitamin C are calculated in the said composition by mass percentage, pear powder layer 18-50%, syngnathus and mud eel powder 10-40%, Borax 2-15%, Borneolum Syntheticum 1-5%, Radix Notoginseng powder 1.3-9%, sodium benzoate 0.02-0.3%, phenytoin Sodium 5-30%, vitamin C 0.5-5%.
2, medicine ' Suyusan ' for treating intractable ulcer as claimed in claim 1 is characterized in that pear powder layer is made up of southern pearl powder and Margarita layer powder, and it is 1: 4 that they the two proportioning is calculated according to the mass fraction.
3, medicine ' Suyusan ' for treating intractable ulcer as claimed in claim 1 is characterized in that syngnathus and mud eel powder by Endoconcha Sepiae, and Os Draconis and Monopteri albi dry powder are formed, and their threes' proportioning is calculated as 1: 1: 1 by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011405104A CN1199666C (en) | 2001-09-17 | 2001-09-17 | Medicine 'Suyusan' for treating intractable ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011405104A CN1199666C (en) | 2001-09-17 | 2001-09-17 | Medicine 'Suyusan' for treating intractable ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1342491A true CN1342491A (en) | 2002-04-03 |
| CN1199666C CN1199666C (en) | 2005-05-04 |
Family
ID=4675922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011405104A Expired - Fee Related CN1199666C (en) | 2001-09-17 | 2001-09-17 | Medicine 'Suyusan' for treating intractable ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1199666C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120095008A1 (en) * | 2009-03-25 | 2012-04-19 | Keshav Malshe | Composition and methods for the treatment of wounds |
| US8389025B2 (en) | 2006-12-15 | 2013-03-05 | Paradigm, Inc. | Compositions to alleviate herpes virus symptoms |
| US8673373B2 (en) | 2006-12-15 | 2014-03-18 | Paradigm, Inc. | Homeopathic formulations for treatment of herpes virus symptoms |
| US20140093593A1 (en) * | 2012-10-02 | 2014-04-03 | North Texas Medical Associates | Decubitus Treatment System |
-
2001
- 2001-09-17 CN CNB011405104A patent/CN1199666C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8389025B2 (en) | 2006-12-15 | 2013-03-05 | Paradigm, Inc. | Compositions to alleviate herpes virus symptoms |
| US8673373B2 (en) | 2006-12-15 | 2014-03-18 | Paradigm, Inc. | Homeopathic formulations for treatment of herpes virus symptoms |
| US20120095008A1 (en) * | 2009-03-25 | 2012-04-19 | Keshav Malshe | Composition and methods for the treatment of wounds |
| US8772324B2 (en) * | 2009-03-25 | 2014-07-08 | Keshav Malshe | Composition and methods for the treatment of wounds |
| US20140093593A1 (en) * | 2012-10-02 | 2014-04-03 | North Texas Medical Associates | Decubitus Treatment System |
| US8945637B2 (en) * | 2012-10-02 | 2015-02-03 | Aloe Bioscience, Llc | Decubitus treatment system |
| US9750781B2 (en) | 2012-10-02 | 2017-09-05 | Aloe Bioscience, Llc | Decubitus treatment system |
| US20170333513A1 (en) * | 2012-10-02 | 2017-11-23 | Aloe Bioscience, Llc | Decubitus Treatment System |
| US10835569B2 (en) * | 2012-10-02 | 2020-11-17 | Aloe Bioscience, Llc | Decubitus treatment system |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1199666C (en) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893458B (en) | Diabetic foot ulcer external medicine composition, preparation method and applications | |
| CN112618646A (en) | Traditional Chinese medicine composition and traditional Chinese medicine oil for treating burns and preparation method thereof | |
| CN1199666C (en) | Medicine 'Suyusan' for treating intractable ulcer | |
| CN1679745A (en) | External-applied medicine for treating burn, valnus and local tumor inflammation | |
| CN102283887B (en) | Ointment for treating burn | |
| CN101152290B (en) | Externally used powder preparation stypticum | |
| CN1068785C (en) | Chinese patent medicine for external application for curing diseases of scald, burn and dermal ulcer | |
| CN1259087C (en) | Medicine for treating trauma and sores and its preparing process | |
| CN1935267A (en) | Wound surface active repair material | |
| CN103690903A (en) | Compound traditional Chinese medicine preparation for treating trauma diseases such as burn, scald, bedsore and the like | |
| CN114010669A (en) | Ointment for removing putrefaction and promoting tissue regeneration and preparation method and application thereof | |
| CN113546158A (en) | A kind of wound care ointment and preparation process thereof | |
| CN101028365A (en) | Medicine for treating burn and ambustion and its production | |
| CN1317017C (en) | Externally applied medicine for treating skin ulcer | |
| CN101647952A (en) | Flesh engendering and wound closing medicament for external use | |
| CN107982300B (en) | Spray and preparation method and application thereof | |
| CN1255184C (en) | Medication use for external application of glucose-insulin-potassium polarization liquid for curing trauma and burn | |
| CN1167430C (en) | Broad-spectrum antibacterial Huangru Ointment for treating deep burn | |
| CN1297292C (en) | Burn treating medicine | |
| CN1236798C (en) | External medicine for treating bone tuberculosis | |
| CN1408382A (en) | Medicine for curing bed sore and ulcer | |
| CN1876085A (en) | A Chinese medicinal ointment for promoting wound healing after anal fistula operation and preparation method thereof | |
| CN1720971A (en) | Stomatocace powder | |
| CN1911231A (en) | Medicine for treating burns | |
| CN1064534C (en) | Medicine for skin disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |